Cyclacel Pharmaceuticals

OverviewSuggest Edit

Cyclacel Pharmaceuticals develops oral therapies to treat cancers and other serious diseases, particularly those of high unmet medical need, with a vision to improve patient healthcare with orally available innovative medicines. The Company’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

TypePublic
Founded1992
HQBerkeley Heights, NJ, US
Websitecyclacel.com

Latest Updates

Employees (est.) (Mar 2020)12(-14%)
Revenue (FY, 2018)$150 K
Share Price (Apr 2021)$6.5
Cybersecurity ratingAMore

Key People/Management at Cyclacel Pharmaceuticals

Christopher S. Henney

Christopher S. Henney

Chairman
Paul McBarron

Paul McBarron

Executive Vice President, Finance and Chief Operating Officer and Secretary
Robert J. Spiegel

Robert J. Spiegel

Vice-Chairman
Mark H. Kirschbaum

Mark H. Kirschbaum

Senior Vice President, Chief Medical Officer
Judy Chiao

Judy Chiao

Vice President, Clinical Development and Regulatory Affairs
Amartya Basu

Amartya Basu

Senior Director, Project Management and Business Development
Show more

Cyclacel Pharmaceuticals Office Locations

Cyclacel Pharmaceuticals has offices in Berkeley Heights and Dundee City
Berkeley Heights, NJ, US (HQ)
200 Connell Dr #1500
Dundee City, GB
1 James Lindsay Pl
Show all (2)

Cyclacel Pharmaceuticals Financials and Metrics

Cyclacel Pharmaceuticals Revenue

Cyclacel Pharmaceuticals's revenue was reported to be $150 k in FY, 2018
USD

Net income (FY, 2020)

(8.4m)

EBIT (FY, 2020)

(10.6m)

Market capitalization (19-Apr-2021)

59.5m

Closing stock price (19-Apr-2021)

6.5

Cash (31-Dec-2020)

33.4m

EV

27.2m
Cyclacel Pharmaceuticals's current market capitalization is $59.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

699.0k69.0k1.1m1.7m1.9m843.0k150.0k

Revenue growth, %

60%12%(57%)

Cost of goods sold

360.0k

Gross profit

339.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

168.0k164.0k161.0k146.0k38.0k212.0k264.0k309.0k396.0k356.0k735.0k512.0k296.0k715.0k139.0k205.0k

Cost of goods sold

72.0k95.0k94.0k89.0k

Gross profit

96.0k69.0k67.0k57.0k

Gross profit Margin, %

57%42%42%39%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

24.4m16.4m31.1m24.2m20.4m16.5m23.9m17.5m11.9m33.4m

Prepaid Expenses

1.2m1.6m3.4m4.6m4.1m2.1m2.3m2.1m2.1m

Inventories

182.0k

Current Assets

25.8m18.9m35.2m29.0m24.6m19.6m26.0m19.8m14.0m35.5m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

20.6m27.7m23.6m20.0m17.8m14.1m33.7m34.5m28.2m33.5m26.7m29.4m26.9m22.7m17.1m15.9m18.0m12.7m13.6m26.0m21.7m19.8m19.0m17.9m15.2m13.0m8.9m25.3m

Accounts Receivable

45.0k

Prepaid Expenses

1.7m941.0k1.4m1.6m1.2m2.1m2.7m2.4m4.7m3.4m4.2m5.5m3.5m4.0m4.1m2.8m4.5m4.3m2.5m1.8m3.0m2.9m1.7m2.2m3.0m2.9m2.9m2.6m

Inventories

147.0k165.0k109.0k50.0k
USDQ2, 2011

Financial Leverage

1.4 x
Show all financial metrics

Cyclacel Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Cyclacel Pharmaceuticals Online and Social Media Presence

Embed Graph

Cyclacel Pharmaceuticals News and Updates

Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

BERKELEY HEIGHTS, N.J., March 16, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously announced un…

Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common Stock

BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of an underwritten public offe…

Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock

BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it intends to offer shares of its com…

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results

BERKELEY HEIGHTS, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2020 financial r…

Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference

BERKELEY HEIGHTS, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the 2021 B…

Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021

– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–– Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer –– $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures–
Show more

Cyclacel Pharmaceuticals Blogs

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Content Import Thu, 02/25/2021 - 16:09 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results 02/25/21 This release is a backfill from a News Wi…

Cyclacel Pharmaceuticals to Release Third Quarter Financial Results

Cyclacel Pharmaceuticals to Release Third Quarter Financial Results Content Import Thu, 11/05/2020 - 09:30 Cyclacel Pharmaceuticals to Release Third Quarter Financial Results 11/05/20 This release is a backfill from a News Wire General …

Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer

Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer Content Import Fri, 10/23/2020 - 16:31 Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer 10/23/20 This release is…

Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results

- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J. , Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell

Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results

Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results Content Import Wed, 08/05/2020 - 07:03 Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results 08/05/20 This release is a backfill from a News Wire Gene…

Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer

Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer Content Import Mon, 07/13/2020 - 07:01 Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer 07/13/…
Show more

Cyclacel Pharmaceuticals Frequently Asked Questions

  • When was Cyclacel Pharmaceuticals founded?

    Cyclacel Pharmaceuticals was founded in 1992.

  • Who are Cyclacel Pharmaceuticals key executives?

    Cyclacel Pharmaceuticals's key executives are Christopher S. Henney, Paul McBarron and Robert J. Spiegel.

  • How many employees does Cyclacel Pharmaceuticals have?

    Cyclacel Pharmaceuticals has 12 employees.

  • Who are Cyclacel Pharmaceuticals competitors?

    Competitors of Cyclacel Pharmaceuticals include WuXi AppTec, Tergus Pharma and Bristol-Myers Squibb.

  • Where is Cyclacel Pharmaceuticals headquarters?

    Cyclacel Pharmaceuticals headquarters is located at 200 Connell Dr #1500, Berkeley Heights.

  • Where are Cyclacel Pharmaceuticals offices?

    Cyclacel Pharmaceuticals has offices in Berkeley Heights and Dundee City.

  • How many offices does Cyclacel Pharmaceuticals have?

    Cyclacel Pharmaceuticals has 2 offices.